Citadel Advisors - AKERO THERAPEUTICS INC ownership

AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of AKERO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$19,690,137
+12.2%
389,287
+3.6%
0.00%
+33.3%
Q2 2023$17,550,397
-50.8%
375,892
-59.7%
0.00%
-57.1%
Q1 2023$35,700,712
+50.6%
933,108
+115.7%
0.01%
+16.7%
Q4 2022$23,707,412
+88.5%
432,617
+17.1%
0.01%
+100.0%
Q3 2022$12,576,000
+1249.4%
369,361
+274.6%
0.00%
Q2 2022$932,000
-25.2%
98,610
+12.3%
0.00%
Q1 2022$1,246,000
+114.8%
87,810
+220.0%
0.00%
Q4 2021$580,000
-45.1%
27,439
-42.0%
0.00%
Q3 2021$1,057,000
-47.9%
47,269
-42.3%
0.00%
Q2 2021$2,030,000
-65.5%
81,862
-59.6%
0.00%
-100.0%
Q1 2021$5,877,000
+1.1%
202,575
-10.1%
0.00%0.0%
Q4 2020$5,815,000
+364.1%
225,404
+453.9%
0.00%
Q3 2020$1,253,000
-24.0%
40,691
-38.5%
0.00%
-100.0%
Q2 2020$1,648,000
+454.9%
66,115
+372.2%
0.00%
Q1 2020$297,000
-35.3%
14,000
-32.4%
0.00%
Q4 2019$459,000
-13.1%
20,702
-10.8%
0.00%
Q3 2019$528,00023,2190.00%
Other shareholders
AKERO THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
ATP Life Science Ventures, L.P. 5,830,203$179,512,00024.20%
venBio Partners LLC 2,444,311$75,260,00011.44%
Versant Venture Management, LLC 777,727$23,946,0004.38%
Redmile Group, LLC 2,336,357$71,936,0001.32%
Vivo Capital, LLC 571,833$17,607,0001.02%
Cormorant Asset Management, LP 859,550$26,466,0001.02%
Boxer Capital, LLC 831,495$25,602,0000.88%
Integral Health Asset Management, LLC 85,000$2,617,0000.80%
EAM Global Investors LLC 49,718$1,531,0000.56%
Crawford Lake Capital Management, LLC 43,826$1,349,0000.56%
View complete list of AKERO THERAPEUTICS INC shareholders